Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adefovir and Nelfinavir in Pediatric HIV
NCT00002219Phase 2Unknown
- Sponsor
- Gilead Sciences
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of adefovir dipivoxil in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Pharmacokinetics of Adefovir at Day 28 and Safety and Tolerability at Week 16. Status: unknown.
02
Drugs
adefovir dipivoxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002219.